Noopept nasal spray: separating hype from thin human evidence

What did @jacobnickelsonn actually say?

The creator reviewed intranasal Noopept, claiming it "increases BDNF, NGF" and helps with "memory, learning, verbal fluency." He recommended starting at 2-5 mg intranasally rather than the 10-30 mg oral doses listed online, arguing oral bioavailability is poor. He rated it 8 out of 10 for cognitive enhancement and mentioned it "ameliorates glutamate levels" as part of its mechanism. He also noted that taking too much can cause irritability.

To his credit, he was measured. He didn't claim it cures anything, he acknowledged the benefits aren't dramatic, and he flagged a potential side effect. For a TikTok nootropics review, that's a relatively responsible framing. But several of his specific mechanistic claims deserve closer examination, because the evidence base for Noopept in humans is thinner than his confidence level suggests.

Does the science back this up?

The BDNF and NGF claims have some preclinical support, but the human evidence is sparse and underpowered. This is a compound with real pharmacology, but calling it an 8 out of 10 nootropic based on current data is getting ahead of the research.

Noopept (omberacetam) is a synthetic dipeptide originally developed in Russia. Animal studies, including work by Ostrovskaya et al. (2008, Bulletin of Experimental Biology and Medicine), showed increased NGF and BDNF expression in rat hippocampus after Noopept administration. That's interesting. It's also rat data.

The human clinical trials that exist are small, often industry-adjacent, and conducted primarily in Russian populations with cognitive impairment, not healthy adults trying to "talk a little bit smoother." A 2014 trial by Neznamov and Teleshova (Journal of Psychopharmacology) looked at Noopept in mild cognitive disorders and found some benefit, but the sample was small and the population doesn't map cleanly onto healthy optimization use cases.

On bioavailability: the creator is correct that oral bioavailability is considered low, and intranasal delivery is a real pharmacological rationale for peptide-adjacent compounds. But controlled pharmacokinetic data for intranasal Noopept in humans is essentially nonexistent in the peer-reviewed literature.

What did they get wrong (or right)?

The glutamate claim was garbled. The creator said Noopept "ameliorates glutamate levels," which is an imprecise description of the actual proposed mechanism. He got the BDNF and NGF angle roughly right. The oral bioavailability point is directionally accurate. The dosing logic is reasonable but stated with more confidence than the data warrants.

What Noopept actually appears to do, based on preclinical work, is modulate AMPA receptors and inhibit glutamate excitotoxicity, not simply lower glutamate. Saying it "ameliorates glutamate levels" conflates a neuroprotective mechanism with a straightforward reduction in neurotransmitter concentration. These aren't the same thing, and the distinction matters when people are deciding whether to put something in their nose.

The BDNF and NGF claims are the strongest part of his argument, and he's not wrong to cite them, but he presents animal findings as though they're settled human physiology. They're not. The claim that it improves verbal fluency and conversation in healthy adults has no controlled trial support that holds up to scrutiny.

The irritability warning at higher doses is accurate and worth keeping. That's a reported adverse effect.

What should you actually know?

Noopept is unscheduled in the US but is not FDA-approved for any indication. Intranasal administration of any compound carries risks that most TikTok reviews don't address, including local mucosal irritation and unpredictable absorption. The regulatory and safety picture here is genuinely unclear.

If you're considering Noopept, the honest summary is this: the mechanistic rationale is plausible, the animal data is mildly encouraging, and the human evidence is thin. That's not the same as saying it doesn't work. It means we don't have good data either way for healthy adults using it as a cognitive enhancer.

Intranasal peptide and peptide-adjacent compounds are increasingly popular, but "it feels good to me" is not a substitute for pharmacokinetic data. Anyone using unregulated intranasal compounds should understand they are outside the bounds of any approved medical use and should consult a licensed clinician before starting.

• Noopept is not approved by the FDA for any medical use
• Most human trials involve cognitively impaired populations, not healthy adults
• Intranasal bioavailability data in humans is not available in peer-reviewed literature
• BDNF and NGF increases are primarily documented in rodent models
• Self-reported cognitive improvement is subject to significant placebo effects